Skip to main content

Day: March 2, 2026

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

Written by Customer Service on . Posted in Mergers And Acquisitions.

ZURICH, SWITZERLAND – March 2, 2026 — VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting (“EGM”) on February 27, 2026. Both resolutions are prerequisites for the closing of the proposed business combination (the “Business Combination”) among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC. The merger will be carried out by means of an absorption merger. Veraxa Biotech Holding AG, as the acquiring company, will take...

Continue reading

Photonis Defense awarded U.S. Army BiNOD contract for advanced night vision solutions, a strategic milestone for Exosens’ expansion in the U.S.

Written by Customer Service on . Posted in Public Companies.

PHOTONIS DEFENSE AWARDED U.S. ARMY BINOD CONTRACT FOR ADVANCED NIGHT VISION SOLUTIONS, A STRATEGIC MILESTONE FOR EXOSENS’ EXPANSION IN THE U.S.Firm-fixed-price Indefinite Delivery/Indefinite Quantity (IDIQ) contract awarded by the U.S. Army Contracting Command to Photonis Defense, Exosens’ U.S. subsidiary, with a maximum value of US$352.6 million Contract covers the development, production, and testing of the U.S. Army’s Binocular Night Observation Device (BiNOD) program through February 27, 2033 Award marks a key milestone in Exosens’ expansion in the U.S., the world’s most demanding single market for night vision devices, supported by the Group’s scalable industrial footprint in the countryPress release, Mérignac (France), March 2, 2026 – Exosens (EXENS; FR001400Q9V2), a high-tech company focused on providing mission- and performance-critical...

Continue reading

LERØY SEAFOOD GROUP ASA CMD 2026: INCREASED RETURNS DRIVEN BY SUSTAINABLE GROWTH WITH COST AND CAPITAL DISCIPLINE

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Bergen, Norway, 2 March 2026: Lerøy Seafood Group ASA (“Lerøy”) today presents an updated strategy and clear financial targets towards 2030 at its Capital Markets Day (CMD). Building on a fully integrated seafood value chain, strengthened biological performance and a disciplined investment programme, Lerøy enters a new phase focused on scalable growth, structural cost reductions and improved capital efficiency. The strategy is anchored in four priorities — Growth, Cost, Simplify and Leadership —through the Lerøy Way execution model and supported by a sharpened capital allocation framework. Lerøy Seafood Group targets towards 2030:NOK 50 billion in revenues   NOK 2 billion EBIT in VAP S&D Targeting NOK 1 billion in reduced cost base through initiatives in 2026Targeting NOK 1 billion in reduced cost base through initiatives in 2026 15%...

Continue reading

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

Written by Customer Service on . Posted in Public Companies.

BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs. In December 2025, zurletrectinib received approval for the treatment of adult and adolescent patients (aged 12 years...

Continue reading

PONY AI Inc. Achieved Gen-7 Robotaxi UE Breakeven in Shenzhen, Strengthening Path to Scalable Commercialization

Written by Customer Service on . Posted in Public Companies.

SHENZHEN, China, March 02, 2026 (GLOBE NEWSWIRE) — Pony AI Inc. (“Pony.ai” or the “Company”) (NASDAQ: PONY; HKEX: 2026), a global leader in achieving large-scale mass production and commercialization of autonomous driving technology, today announced that it has achieved seventh-generation (“Gen-7”) Robotaxi unit economics (“UE”) breakeven1 in Shenzhen. This milestone underscores Pony.ai’s capability to realize a sustainable business model, laying a solid foundation to accelerate scale-up over a multi-year horizon. Driven by surging user demand and optimized operational efficiency, Pony.ai’s commercial operations in Shenzhen have delivered outstanding results. As of February 28, the one-month daily average net revenue per Gen-7 Robotaxi has reached RMB338, with a daily average of 23 orders per vehicle. These figures demonstrate...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.